A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

Exclusion Criteria

• •Transformation to high-grade lymphoma
• •Aggressive lymphoma (for example, mantle cell lymphoma \[MCL\])
• •Presence or history of central nervous system (CNS) lymphomatous disease
• •Other malignancy within 5 years prior to enrollment, except for curatively treated carcinoma in situ of the cervix, squamous cell carcinoma of the skin or basal cell skin cancer, or cervical carcinoma Stage 1B or less, breast cancer in situ or localized prostate cancer Stage T1c if treated with curative intent and relapse- and metastasis-free for at least 2 years prior to enrollment
• •Inadequate hematological, hepatic or renal function
• •Known human immunodeficiency virus (HIV) infection
• •Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections, active hepatitis B or C)
• •Pregnant or breastfeeding women